Rheumatology

A randomised trial has found that early DMARD therapy improves short-term disease activity in undifferentiated arthritis, though long-term outcomes remained similar.

A phase II trial found the MK2 inhibitor CC-99677 was well tolerated but failed to significantly improve ankylosing spondylitis symptoms.

Patients receiving vunakizumab for radiographic axial spondyloarthritis demonstrated improved clinical responses through 32 weeks, a new trial has shown.

Researchers reported significant dose-dependent improvements in lupus skin disease activity with the oral TLR7/8 inhibitor enpatoran.

Systemic lupus erythematosus was associated with lower second delivery rates and recurrent pregnancy complications in a nationwide study.

Long-term tofacitinib treatment in juvenile idiopathic arthritis was associated with normal growth and stable hormone biomarkers.

Researchers have found that IL-17 inhibitors are associated with lower psoriatic arthritis risk after biologic switching in psoriasis.

Low-dose glucocorticoid treatment caused modest lumbar spine bone loss in rheumatoid arthritis over two years, a meta-analysis finds.